Represented appellee Watson Pharmaceuticals, Inc. in successful defense of district court’s order dismissing Bayer’s claims of patent infringement. The Federal Circuit agreed with Watson that for a generic drug maker to infringe a method-of-use patent, the proposed label must indicate that the drug is approved (i.e., safe and effective) for the claimed method. Bayer Schering Pharma AG v. Lupin, Ltd., et al., 2012 U.S. App. LEXIS 7570, Fed. Cir. Appeal No. 2011-1143 (April 16, 2012).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Matter alleging various business torts against Progress Energy Inc. and Carolina Power & Light Co. d/b/a Progress Energy
Represented Progress Energy in a complex matter alleging various business torts, including tortious interference with contract and unfair and more
Unfair competition actions on behalf of major bottled water company
Represented a major bottled water company in unfair competition actions relative to advertising claims. more
Sale of telecommunications and entertainment company to venture capital fund
Represent telecommunications and entertainment company as seller's counsel in connection with the company's sale to a venture capital/investment fund. more
Alternative dispute resolution for a Las Vegas-based developer
Represented a Las Vegas-based developer/owner in a complex $85 million arbitration with its general contractor. The dispute arose out of the more